LILRB2 blockade modulates macrophages and other myeloid cells in cancer immunotherapy

Leukocyte immunoglobulin-like receptor B2 (LILRB2), also known as immunoglobulin-like transcript 4 (ILT4), is an inhibitory receptor expressed in monocytes, macrophages, dendritic cells and neutrophils and, in selected cancers, malignant cells. The abundance and presentation of HLA class I molecules and other tumor-associated ligands help determine where this inhibitory pathway operates. Antagonistic antibodies have entered clinical development alone and with PD-(L)1 blockade. Across independent human monocyte-derived macrophage systems, antagonism shifts differentiation, increases inflammatory cytokine output and improves support for T-cell activation or tumor-cell killing. Tumor explants and humanized or transgenic mouse models show related changes in mixed myeloid populations. Dendritic cells, suppressive myeloid cells and malignant cells also alter immunity and tumor control through LILRB2-dependent or parallel routes. Transcriptomic and proteomic studies associate this macrophage response with lipid handling, endocytic transport and antigen presentation. Phase I studies of MK-4830 and IO-108 show sustained peripheral target occupancy and preliminary activity, and randomized MK-4830 studies provide initial comparative estimates for pembrolizumab-based combinations. LILRB2 is therefore best viewed as a broader myeloid-modulating target, with macrophage activity as a prominent component whose contribution to treatment response may differ among tumors. Patient selection and evaluation of PD-(L)1 combinations should incorporate tumor ligand availability, receptor-bearing cell composition and paired intratumoral measurements of target engagement, macrophage function and local T-cell activity.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-20
DOI
https://doi.org/10.1007/s12672-026-06299-w
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

LILRB2 blockade modulates macrophages and other myeloid cells in cancer immunotherapy

Jie Zhang, Dongzhe Li
2 links
Discover Oncology
Cancer Immunotherapy and Biomarkers
article

LILRB2 blockade modulates macrophages and other myeloid cells in cancer immunotherapy

Jie Zhang, Dongzhe Li
article en

Abstract

Leukocyte immunoglobulin-like receptor B2 (LILRB2), also known as immunoglobulin-like transcript 4 (ILT4), is an inhibitory receptor expressed in monocytes, macrophages, dendritic cells and neutrophils and, in selected cancers, malignant cells. The abundance and presentation of HLA class I molecules and other tumor-associated ligands help determine where this inhibitory pathway operates. Antagonistic antibodies have entered clinical development alone and with PD-(L)1 blockade. Across independent human monocyte-derived macrophage systems, antagonism shifts differentiation, increases inflammatory cytokine output and improves support for T-cell activation or tumor-cell killing. Tumor explants and humanized or transgenic mouse models show related changes in mixed myeloid populations. Dendritic cells, suppressive myeloid cells and malignant cells also alter immunity and tumor control through LILRB2-dependent or parallel routes. Transcriptomic and proteomic studies associate this macrophage response with lipid handling, endocytic transport and antigen presentation. Phase I studies of MK-4830 and IO-108 show sustained peripheral target occupancy and preliminary activity, and randomized MK-4830 studies provide initial comparative estimates for pembrolizumab-based combinations. LILRB2 is therefore best viewed as a broader myeloid-modulating target, with macrophage activity as a prominent component whose contribution to treatment response may differ among tumors. Patient selection and evaluation of PD-(L)1 combinations should incorporate tumor ligand availability, receptor-bearing cell composition and paired intratumoral measurements of target engagement, macrophage function and local T-cell activity.

Discover Oncology
Central Hospital Affiliated to Shenyang Medical College (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
LILRB2 blockade modulates macrophages and other myeloid cells in cancer immunotherapy — Jie Zhang, Dongzhe Li · Discover Oncology (2026) | TGRS Research Map | TGRS